System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Christelle Fouchardiere is an expert in Oncology at Centre Léon Bérard (France). As of October 2026, ScienceLeadR ranks Christelle Fouchardiere in the top 1% of experts worldwide for Carcinoma, Rectal Diseases and Gastrointestinal Neoplasms. Christelle Fouchardiere has authored 377 publications, the most recent in 2026, and is an investigator in 70 clinical trials, 18 of them ongoing. SLR score: 2,221 (community average: 125). How the SLR is computed.

LeadR Profile

Christelle Fouchardiere Centre Léon Bérard France
2 221 ScienceLeadR Reputation 2221

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Endocrinology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Centre Léon Bérard

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 377

Citations

Citations: 24 529 1st author: 38 Last author: 31 Unique author: 13

Main journals

J Clin Oncol 86
Ann Oncol 64
Eur J Cancer 23
Ann Endocrinol (Paris) 14
ESMO Open 10

Best Journals

J Clin Oncol 49
Ann Oncol 46
N Engl J Med 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?
PMID 42232843 — quality of life, colostomy, brachytherapy, chemoradiotherapy, fecal incontinence, anal canal, therapeutics		J Contemp Brachytherapy20260
Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group.
PMID 42155363 — neoplasms, gastrointestinal tract, gastrointestinal neoplasms		Eur J Cancer20260
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
PMID 42097353 — safety, paclitaxel, anus neoplasms, neoplasms, immunotherapy, therapeutics, carboplatin		Ann Oncol Top journal20260
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.
PMID 41980235 — dna mismatch repair, microsatellite repeats, safety, neoplasms, colorectal neoplasms, mmr-deficient		J Clin Oncol Top journal20260
Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.
PMID 41865627 — skin, cells, carcinoma, squamous cell, neoplasms, body composition, drug therapy, panitumumab, research, therapeutics, pharmacokinetics		Biomed Pharmacother20260

Clinical Studies 70

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 15

By phase:

Phase 2 40
Phase 3 18
N/A 7
Phase 2/Phase 3 3
Phase 1/Phase 2 2

By status:

Completed 30
Active not recruiting 13
Recruiting 13
Unknown 6
Terminated 5
Not yet recruiting 3

By type:

Interventional 67
Observational 3

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 5
multicentric5to9 10
multicentricup10 46

Main Topics

Ongoing Clinical Trials

18 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Randomized Active Controlled Double blind Multicenter Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First line Treatment of Metastatic Colorectal Cancer (HARMONi GI3)
2025-521587-35-00 — neoplasms, bevacizumab, response evaluation criteria in solid tumors, therapeutics, colorectal neoplasms		Phase 3Recruiting2026
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated Unresectable or Metastatic Colorectal Cancer
2025-523224-45-00 — pharmaceutical preparations, neoplasms, bevacizumab, drug therapy, colorectal neoplasms, chemotherapy		Phase 2/Phase 3Not yet recruiting2026
SPARTANA Spartalizumab mDCF (docetaxel cisplatin and 5 fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma
2024-516005-23-00 — radiotherapy, cells, docetaxel, fluorouracil, carcinoma		Phase 2Active not recruiting2024
Study aiming to compare the survival of patients with locally advanced or metastatic MSI dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab balstilimab) versus the standard of care (FOLFOX XELOX nivolumab)
2023-506291-28-00 — neoplasms, adenocarcinoma, immune checkpoint inhibitors, nivolumab, stomach neoplasms, mmr-deficient, msi-h		Phase 3Recruiting2026
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07359456 — leucovorin, research design, dna mismatch repair, microsatellite repeats, neoplasms, bevacizumab, drug therapy, liver, fluorouracil, neoplasm metastasis, colorectal neoplasms, infusions, intravenous, irinotecan, chemotherapy		Phase 2Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS